Charlie Fuchs, Genentech global head of oncology

#AS­CO22: Fol­low­ing back-to-back TIG­IT bombs, Roche of­fers in­sight in­to first PhI­II tri­al fail

Roche’s Genen­tech suf­fered two con­sec­u­tive Phase III fails for tiragolum­ab, the ear­li­est in a se­ries of an­ti-TIG­IT drugs from Big Phar­mas hop­ing to ush­er in the next gen­er­a­tion of im­mune check­point ther­a­pies.

To­day, the Swiss phar­ma un­veiled spe­cif­ic da­ta on SKY­SCRAPER-02, the first tri­al that flopped, which test­ed tiragolum­ab along­side Tecen­triq and chemother­a­py as a first line of treat­ment in pa­tients with ex­ten­sive stage small cell lung can­cer. Com­pared to an av­er­age over­all sur­vival of 12.9 months with on­ly Tecen­triq and chemother­a­py, the ad­di­tion of tiragolum­ab failed to move the nee­dle at all, with an over­all sur­vival of 13.1 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.